Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) fair value: what the stock is really worth
As of Nov 3, 2026: fair value (intrinsic value) of Biotrend Cevre ve Enerji Yatirimlari AS stock TRY 8.19, price TRY 10.22, that is 19.9% below the price, quality 23 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range 4.74 TRY – 27.12 TRY · fair‑value band 3.62 TRY – 16.07 TRY · the 10.22 TRY price screens above the 8.19 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Biotrend Cevre ve Enerji Yatirimlari AS in your weekly email
Every Wednesday you see whether Biotrend Cevre ve Enerji Yatirimlari AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biotrend Cevre ve Enerji Yatirimlari A.S. engages in integrated waste management-oriented renewable energy, circular raw materials, and fuel production activities in Turkey.
Show moreShow less
It is involved in the waste disposal; mechanical sorting; recycled products; refuse-derived fuel; generation of electricity and heat from biogas, landfill gas, and biomass; carbon trading; composting; sanitary landfills; and greenhouse farming.
The company also engages in production of energy using fermentation, , incineration technologies; operation of solid waste storage areas, mechanical separation plant, waste derived fuel preparation plant, leachate treatment plant, biological treatment plant, and landfill gas; and installation and operation of power generation plants, as well as provision of engineering, contracting, and consulting services.
The company was founded in 2017 and is headquartered in Istanbul, Turkey. Biotrend Cevre ve Enerji Yatirimlari A.S. operates as a subsidiary of Doganlar Investment Holding A.S.
Stock analysis
Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) currently trades at 10.22 TRY, while our model-based Fair Value estimate is 8.19 TRY, 19.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 6.50 TRY per share, and 0 of the 8 models we run sit above the 10.22 TRY price.
Bear case: the Asset-Based group reads lowest at 3.20 TRY, and 8 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: 3.62 TRY (bear) to 16.07 TRY (bull), the price of 10.22 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Utilities sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Biotrend Cevre ve Enerji Yatirimlari AS reported revenue of 2.9B TRY in FY2025 versus 428M TRY in FY2021, a compound +62.0%/yr. Reported net income was −1.4B TRY in FY2025.
Key figures
Market cap 5.1B TRY (≈ $102M) Micro · P/E ratio 2.6 · P/S ratio 2.00 · EPS (TTM) 3.94 TRY · Net margin −47.0% · Return on equity −18.0% · Return on assets (EBIT) 1.2% · Operating margin −17.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 55% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Utilities peers we cover trades at −50% fair-value upside, at −20%, BIOEN screens cheaper than that median.
Fair Value models
Bear3.62 TRYFair Value 8.19 TRYBull16.07 TRY
Price 10.22 TRY · Downside -19.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.31 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−17.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
28.2% (2020) → −18.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+48.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Turkey: IMF forecast 19.3% a year to 2030, 28.5% from 2016 to 2025) that is about +24.5% a year for the price.
Compare Biotrend Cevre ve Enerji Yatirimlari AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Utilities - Renewable · 200 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−18.1% · Below median
Profitability
Return on assets−14.3% · Bottom 25%
Net margin (12 months)−25.3% · Bottom 25%
Operating margin (12 months)−17.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−9.0% · Below median
Balance sheet
Debt / equity1.22× · Above median
Valuation Multiplesvs Utilities - Renewable median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biotrend Cevre ve Enerji Yatirimlari AS Fair Value". https://www.fairvalue-calculator.com/stock/BIOEN
Frequently asked questions
Is Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of 8.19 TRY versus a price of 10.22 TRY, about 20% lower (overvalued).
What is the fair value of BIOEN?
Our model-based fair value for Biotrend Cevre ve Enerji Yatirimlari AS is 8.19 TRY (as of Nov 2, 2026), built from audited fundamentals. The current price: 10.22 TRY.
What is the quality score of BIOEN?
Biotrend Cevre ve Enerji Yatirimlari AS has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Our model-based price target is the fair value of 8.19 TRY (as of Nov 2, 2026) from 8 valuation models. Cautious scenario 3.62 TRY, optimistic scenario 16.07 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Biotrend Cevre ve Enerji Yatirimlari AS stock forecast for 2026?
Our models put fair value at 8.19 TRY, about 20% lower versus a price of 10.22 TRY (overvalued). Cautious scenario 3.62 TRY, optimistic scenario 16.07 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Biotrend Cevre ve Enerji Yatirimlari AS reported trailing-twelve-month revenue of about 2.6B TRY (latest available figure, as of Nov 2, 2026).
What growth is priced into Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
For today's price to be fair in a discounted-cash-flow model, Biotrend Cevre ve Enerji Yatirimlari AS would have to grow free cash flow by +48.5 % per year for five years (discount rate 15.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +64.4 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of BIOEN use?
Our models discount Biotrend Cevre ve Enerji Yatirimlari AS at 15.7 %: a base by market capitalisation (micro), damped by beta 0.37, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biotrend Cevre ve Enerji Yatirimlari AS that is +48.5 % per year a year over ten years, using the same discount rate (15.7 %) and the same formula as our fair value.
How much growth has Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) delivered so far?
Over the past 5 years revenue at Biotrend Cevre ve Enerji Yatirimlari AS grew +64.4 % a year. The price currently implies +48.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Biotrend Cevre ve Enerji Yatirimlari AS (+48.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The free-cash-flow yield on the price is 3.01 %: that much free cash flow Biotrend Cevre ve Enerji Yatirimlari AS produces per unit of market value. When it exceeds the discount rate of our models (15.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biotrend Cevre ve Enerji Yatirimlari AS it is 8.19 TRY per share (as of Nov 2, 2026), against a price of 10.22 TRY. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Biotrend Cevre ve Enerji Yatirimlari AS stock overvalued or undervalued in 2026?
As of Nov 2, 2026, BIOEN trades above its calculated fair value: price 10.22 TRY, fair value 8.19 TRY, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOEN?
No. The price is what the market pays today (10.22 TRY); the fair value is what the company's own numbers justify (8.19 TRY). For Biotrend Cevre ve Enerji Yatirimlari AS the two are 2.03 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Biotrend Cevre ve Enerji Yatirimlari AS worth?
The market values Biotrend Cevre ve Enerji Yatirimlari AS at about 5.1B TRY (market capitalisation, as of Nov 2, 2026). Per share that is 10.22 TRY; our models calculate a fair value of 8.19 TRY per share.
What do the bullish and bearish scenarios say about BIOEN?
Our models span a range for Biotrend Cevre ve Enerji Yatirimlari AS: cautious scenario 3.62 TRY, base 8.19 TRY, optimistic 16.07 TRY per share (as of Nov 2, 2026, price 10.22 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOEN?
Biotrend Cevre ve Enerji Yatirimlari AS trades at a price-to-earnings ratio of 2.6 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8.19 TRY is built from several models across several years. Other multiples: P/B 1.8, P/S 1.9.
How solid is the balance sheet of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Balance-sheet figures for Biotrend Cevre ve Enerji Yatirimlari AS (as of Nov 2, 2026): return on equity −18.0%, debt of 1.22 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is BIOEN from its 52-week high?
Biotrend Cevre ve Enerji Yatirimlari AS trades at 10.22 TRY, about 55% below its 52-week high of 22.90 TRY and 7% above the low of 9.55 TRY (as of Nov 3, 2026). Distance from the high says nothing about value: that is what the fair value of 8.19 TRY is for.
Which stocks are comparable to Biotrend Cevre ve Enerji Yatirimlari AS?
From the same area (Utilities) we also value China Yangtze Power Co, Huaneng Lancang River Hydropower Inc, VERBUND AG, Ørsted A/S, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biotrend Cevre ve Enerji Yatirimlari AS stock attractive at the current price?
The data as of Nov 2, 2026: price 10.22 TRY, calculated fair value 8.19 TRY (−20%), Quality Score 23/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOEN calculated?
We run Biotrend Cevre ve Enerji Yatirimlari AS through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 8.19 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2 % above its aggregate fair value. Biotrend Cevre ve Enerji Yatirimlari AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The closing price on Nov 3, 2026 was 10.22 TRY. Our model-based fair value is 8.19 TRY, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biotrend Cevre ve Enerji Yatirimlari AS right now?
Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (3.62 TRY to 16.07 TRY). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Biotrend Cevre ve Enerji Yatirimlari AS
How large is the market capitalisation of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The market capitalisation of Biotrend Cevre ve Enerji Yatirimlari AS is 5.1B TRY (≈ $102M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The price-to-sales ratio of Biotrend Cevre ve Enerji Yatirimlari AS is 2.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Earnings per share at Biotrend Cevre ve Enerji Yatirimlari AS are 3.94 TRY (price ÷ EPS = P/E 2.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The net margin of Biotrend Cevre ve Enerji Yatirimlari AS is −47.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The return on equity (ROE) of Biotrend Cevre ve Enerji Yatirimlari AS is −18.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
On an EBIT basis the return on assets of Biotrend Cevre ve Enerji Yatirimlari AS is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
The operating margin of Biotrend Cevre ve Enerji Yatirimlari AS is −17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Revenue at Biotrend Cevre ve Enerji Yatirimlari AS is growing −9.0% versus a year earlier (3y avg +33.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN)?
Earnings per share at Biotrend Cevre ve Enerji Yatirimlari AS are growing +67.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Biotrend Cevre ve Enerji Yatirimlari AS (BIOEN) carry?
The net debt of Biotrend Cevre ve Enerji Yatirimlari AS is 4.9B TRY (fiscal year 2025, ≈ 31.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biotrend Cevre ve Enerji Yatirimlari AS in the live analysis
One click puts Biotrend Cevre ve Enerji Yatirimlari AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 2, 2026